27495798|t|Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital
27495798|a|Breakthrough viridans streptococcal bacteremia (VSB) in patients with hematological malignancy receiving levofloxacin prophylaxis is a major blood stream infection (BSI) occurring during febrile neutropenia. However, clinical data focused on VSB in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients are lacking. The medical records of allo-HSCT recipients who received oral levofloxacin prophylaxis between January 2011 and August 2013 at Toranomon Hospital were reviewed to evaluate breakthrough VSB. Stored viridans streptococcal (VGS) species were identified by using sodA gene sequencing, and were assessed for drug susceptibility. Among the 184 allo-HSCT recipients on levofloxacin prophylaxis, 28 (15.2 %) experienced breakthrough VSB. All of the 28 recipients with VSB were treated with a cefepime - based or piperacillin/tazobactam - based regimen. The susceptibility rates of the VGS strains for levofloxacin, cefepime, piperacillin/tazobactam, meropenem, and vancomycin were 0 %, 95 %, 100 %, 100 %, and 100 %, respectively. Both the MIC50 (minimum inhibitory concentration) and the MIC90 of ceftazidim (0.5 μg/mL and 2 μg/mL, respectively) were higher than the MIC90 of all the other anti-pseudomonal beta-lactams (APBLs). Only 1 VGS strain had a penicillin MIC ≥ 2 μg/mL by the Etest (3.6 %). There were no cases with acute respiratory distress syndrome (ARDS) that was associated with VSB, although the rate of viridans group streptococcal shock syndrome was high (26 %). The crude 30-day mortality rate in the VSB group (10.7 %) did not differ significantly from that in the BSI without VSB group (9.3 %) or non - BSI group (7.0 %) (P = 0.77). Also, VSB was not a risk factor for all-cause mortality up to 60 days following allo-HSCT (P = 0.43). APBL with increased anti-VGS activity (APBL-VA) monotherapy would typically be optimal for treating the VGS strains in this setting. Indication of adding an empiric anti-gram-positive agent to APBL-VA for treating VSB should depend on local factors, such as the susceptibility results. In addition, breakthrough VSB is probably not a major cause of death in allo-HSCT settings, where beta-lactam non-susceptible VGS and the ARDS are rare.
27495798	0	12	Breakthrough	T080	C0444503
27495798	13	46	viridans streptococcal bacteremia	T047	C0152965
27495798	50	95	allogeneic hematopoietic stem cell transplant	T061	C4255274
27495798	96	106	recipients	T101	C0376387
27495798	107	116	receiving	T080	C1514756
27495798	117	129	levofloxacin	T109,T195	C0282386
27495798	130	141	prophylaxis	T061	C0199176
27495798	147	155	Japanese	T083	C0022341
27495798	156	164	hospital	T073,T093	C0019994
27495798	165	177	Breakthrough	T080	C0444503
27495798	178	211	viridans streptococcal bacteremia	T047	C0152965
27495798	213	216	VSB	T047	C0152965
27495798	221	229	patients	T101	C0030705
27495798	235	259	hematological malignancy	T191	C0376545
27495798	260	269	receiving	T080	C1514756
27495798	270	282	levofloxacin	T109,T195	C0282386
27495798	283	294	prophylaxis	T061	C0199176
27495798	300	305	major	T080	C0205164
27495798	306	328	blood stream infection	T047	C0004610
27495798	330	333	BSI	T047	C0004610
27495798	335	344	occurring	T052	C1709305
27495798	345	351	during	T079	C0347984
27495798	352	371	febrile neutropenia	T047	C0746883
27495798	382	395	clinical data	T170	C1516606
27495798	396	403	focused	T169	C1285542
27495798	407	410	VSB	T047	C0152965
27495798	414	459	allogeneic hematopoietic stem cell transplant	T061	C4255274
27495798	461	470	allo-HSCT	T061	C4255274
27495798	472	482	recipients	T101	C0376387
27495798	487	494	lacking	T080	C0332268
27495798	500	515	medical records	T170	C0025102
27495798	519	528	allo-HSCT	T061	C4255274
27495798	529	539	recipients	T101	C0376387
27495798	544	552	received	T080	C1514756
27495798	553	557	oral	T169	C1527415
27495798	558	570	levofloxacin	T109,T195	C0282386
27495798	571	582	prophylaxis	T061	C0199176
27495798	623	641	Toranomon Hospital	T073,T093	C0019994
27495798	647	655	reviewed	T080	C1709940
27495798	659	667	evaluate	T058	C0220825
27495798	668	680	breakthrough	T080	C0444503
27495798	681	684	VSB	T047	C0152965
27495798	693	715	viridans streptococcal	T007	C1140704
27495798	717	720	VGS	T007	C1140704
27495798	722	729	species	T185	C1705920
27495798	735	745	identified	T080	C0205396
27495798	749	754	using	T169	C1524063
27495798	755	764	sodA gene	T028	C0017337
27495798	765	775	sequencing	T059	C1294197
27495798	786	794	assessed	T052	C1516048
27495798	799	818	drug susceptibility	T038	C1326871
27495798	834	843	allo-HSCT	T061	C4255274
27495798	844	854	recipients	T101	C0376387
27495798	858	870	levofloxacin	T109,T195	C0282386
27495798	871	882	prophylaxis	T061	C0199176
27495798	908	920	breakthrough	T080	C0444503
27495798	921	924	VSB	T047	C0152965
27495798	940	950	recipients	T101	C0376387
27495798	956	959	VSB	T047	C0152965
27495798	965	972	treated	T169	C1522326
27495798	980	988	cefepime	T109,T195	C0055003
27495798	991	996	based	T169	C1527178
27495798	1000	1023	piperacillin/tazobactam	T121	C0250480
27495798	1026	1031	based	T169	C1527178
27495798	1032	1039	regimen	T061	C0040808
27495798	1045	1059	susceptibility	T038	C1326871
27495798	1060	1065	rates	T081	C1521828
27495798	1073	1076	VGS	T007	C1140704
27495798	1077	1084	strains	T001	C1518614
27495798	1089	1101	levofloxacin	T109,T195	C0282386
27495798	1103	1111	cefepime	T109,T195	C0055003
27495798	1113	1136	piperacillin/tazobactam	T121	C0250480
27495798	1138	1147	meropenem	T109,T195	C0066005
27495798	1153	1163	vancomycin	T116,T195	C0042313
27495798	1228	1233	MIC50	T059	C0427978
27495798	1235	1267	minimum inhibitory concentration	T059	C0427978
27495798	1277	1282	MIC90	T059	C0427978
27495798	1286	1296	ceftazidim	T109,T195	C0007559
27495798	1340	1346	higher	T080	C0205250
27495798	1356	1361	MIC90	T059	C0427978
27495798	1379	1408	anti-pseudomonal beta-lactams	T121	C1254351
27495798	1410	1415	APBLs	T121	C1254351
27495798	1425	1428	VGS	T007	C1140704
27495798	1429	1435	strain	T001	C1518614
27495798	1442	1452	penicillin	T109,T195	C0220892
27495798	1453	1456	MIC	T059	C0427978
27495798	1474	1479	Etest	T059	C3850116
27495798	1500	1502	no	T169	C1518422
27495798	1503	1508	cases	T169	C0868928
27495798	1514	1549	acute respiratory distress syndrome	T033	C1848829
27495798	1551	1555	ARDS	T033	C1848829
27495798	1566	1581	associated with	T080	C0332281
27495798	1582	1585	VSB	T047	C0152965
27495798	1600	1604	rate	T081	C1521828
27495798	1608	1651	viridans group streptococcal shock syndrome	T047	C0152965
27495798	1656	1660	high	T080	C0205250
27495798	1679	1685	30-day	T079	C0439228
27495798	1686	1700	mortality rate	T081	C0205848
27495798	1708	1711	VSB	T047	C0152965
27495798	1712	1717	group	UnknownType	C0681860
27495798	1731	1734	not	T169	C1518422
27495798	1735	1741	differ	T080	C1705242
27495798	1742	1755	significantly	T078	C0750502
27495798	1773	1776	BSI	T047	C0004610
27495798	1777	1784	without	T080	C0332288
27495798	1785	1788	VSB	T047	C0152965
27495798	1789	1794	group	UnknownType	C0681860
27495798	1806	1809	non	T169	C1518422
27495798	1812	1815	BSI	T047	C0004610
27495798	1816	1821	group	UnknownType	C0681860
27495798	1848	1851	VSB	T047	C0152965
27495798	1856	1859	not	T169	C1518422
27495798	1862	1873	risk factor	T033	C0035648
27495798	1888	1897	mortality	T081	C0205848
27495798	1904	1911	60 days	T079	C0439228
27495798	1912	1921	following	T079	C0332282
27495798	1922	1931	allo-HSCT	T061	C4255274
27495798	1944	1948	APBL	T121	C1254351
27495798	1954	1963	increased	T081	C0205217
27495798	1964	1981	anti-VGS activity	T033	C0243095
27495798	1983	1990	APBL-VA	T033	C0243095
27495798	1992	2003	monotherapy	T061	C0087111
27495798	2023	2030	optimal	T080	C2698651
27495798	2035	2043	treating	T169	C1522326
27495798	2048	2051	VGS	T007	C1140704
27495798	2052	2059	strains	T001	C1518614
27495798	2109	2133	anti-gram-positive agent	T121	C1254351
27495798	2137	2144	APBL-VA	T033	C0243095
27495798	2149	2157	treating	T169	C1522326
27495798	2158	2161	VSB	T047	C0152965
27495798	2179	2184	local	T082	C0205276
27495798	2185	2192	factors	T169	C1521761
27495798	2206	2220	susceptibility	T038	C1326871
27495798	2221	2228	results	T169	C1274040
27495798	2243	2255	breakthrough	T080	C0444503
27495798	2256	2259	VSB	T047	C0152965
27495798	2272	2275	not	T169	C1518422
27495798	2278	2283	major	T080	C0205164
27495798	2284	2298	cause of death	T033	C0007465
27495798	2302	2311	allo-HSCT	T061	C4255274
27495798	2328	2339	beta-lactam	T109,T195	C0282215
27495798	2340	2359	non-susceptible VGS	T007	C1140704
27495798	2368	2372	ARDS	T033	C1848829
27495798	2377	2381	rare	T080	C0522498